Trials / Active Not Recruiting
Active Not RecruitingNCT03964727
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 223 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sacituzumab Govitecan-hziy | Administered intravenously |
Timeline
- Start date
- 2019-10-15
- Primary completion
- 2025-01-15
- Completion
- 2026-12-01
- First posted
- 2019-05-28
- Last updated
- 2026-01-30
- Results posted
- 2026-01-30
Locations
65 sites across 8 countries: United States, Australia, Belgium, Canada, France, Hong Kong, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03964727. Inclusion in this directory is not an endorsement.